



## Protein Kinases and Pseudokinases in Cancers

Guest Editors:

### Dr. Bibiana I. Ferreira

1. Faculdade de Medicina e  
Ciências Biomédicas (FMCB),  
Campus de Gambelas,  
Universidade do Algarve, 8005-  
139 Faro, Portugal  
2. Algarve Biomedical Center  
Research Institute, ABC-RI, 8005-  
139 Faro, Portugal

### Dr. Ana Luísa De Sousa-Coelho

1. Algarve Biomedical Center  
Research Institute, ABC-RI, 8005-  
139 Faro, Portugal  
2. Escola Superior de Saúde  
(ESSUAlg), Campus de Gambelas,  
Universidade do Algarve, 8005-  
139 Faro, Portugal

Deadline for manuscript  
submissions:

**closed (1 May 2024)**

### Message from the Guest Editors

Protein kinases and pseudokinases are a superfamily of proteins and account for about 2% of human genes. This family of proteins mediates the activation of key signaling pathways involved in many biological processes. Hence, mutations affecting these groups of proteins are known to be associated with human tumor onset and progression. Therefore, understanding the fundamental molecular mechanisms by which kinases and pseudokinases modulate cancer development will severely impact the design of more effective inhibitors.

In this Special Issue of *Cancers*, we invite authors to submit contributions that provide novel findings in the field of kinases and pseudokinases. We will cover recent advances on the basic mechanisms by which kinases/pseudokinases modulate cancer development and mechanisms of drug resistance or development of new therapeutic approaches. We welcome results from the basic research, preclinical, or clinical fields. Reviews that highlight new findings in the areas mentioned above are also welcome.

We look forward to receiving your contributions.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)